Table 3.
Incidence of cardiovascular adverse events
| Events | Overall (n = 168) | Normal (n = 118) | HPR (n = 50) | P value |
|---|---|---|---|---|
| Cardiovascular adverse events | 110 (65.48%) | 63 (53.39%) | 47 (94.00%) | <.001* |
| Ischemic events | 93 (55.36%) | 46 (38.98%) | 47 (94.00%) | <.001* |
| Cardiac death | 4 (2.38%) | 1 (0.85%) | 3 (6.00%) | .079 |
| Myocardial infarction | 7 (4.17%) | 3 (1.79%) | 4 (8.00%) | .198 |
| Angina recurrence | 46 (27.38%) | 29 (24.58%) | 17 (34.00%) | .257 |
| Stent thrombosis | 36 (21.43%) | 13 (11.02%) | 23 (46.00%) | <.001* |
| Bleeding events | 17 (10.12%) | 17 (14.41%) | 0 (0%) | <.001* |
| Hemorrhagic apoplexy | 2 (1.19%) | 2 (1.69%) | 0 (0%) | 1.000 |
| Secondary anemia | 9 (5.36%) | 9 (7.63%) | 0 (0%) | .059 |
| Hemorrhage of digestive tract | 6 (3.57%) | 6 (5.08%) | 0 (0%) | .107 |